S202
Clinical - Breast
ESTRO 2026
Digital Poster 211 Male Breast Cancer: A Comparative Analysis of Clinipathological Features and Outcomes Boris A Mueller, Diana Roth O'Brien, Lillian Boe, Isabelle Choi, John Cuaron, Atif J Khan, Simon N Powell, Lior Z Braunstein Radiation Oncology, MSKCC, New York, USA
65 yrs), and the average follow-up duration was 13.7 ± 7.6 months (median: 11.5 m, range: 6 to 34 m). Cancer stage was primarily stage I (8/18, 44.4%). The mean implant volume was 309 ± 85.1 cm3 (median: 300 cm3; range: 185 to 525 cm3). Postoperative Baker grading was mostly grade I (6/18, 33.3%). BAD was most commonly moderate (10/18, 55.6%). Cleavage creation was observed in 78% of patients, whereas 22% showed no cleavage creation. All patients received postoperative RT with an EQD2 of 50 Gy. The interval between reconstruction and the start of radiotherapy averaged 96.1 days (range: 28 to 250 days). The mean CTV was 251.5 ± 178.7 cm ³ (range: 12.8 to 575.9), and the mean total PTV was 484.1 ± 357.0 (range: 39.2 to 1210.1) cm ³ . Correlation analyses revealed that higher BAD grades were significantly associated with larger CTV (p = 0.024, ε² = 0.301) and PTV (p = 0.037, ε² = 0.255), while the presence of cleavage creation was negatively correlated with the mean total PTV (r = - 0.590, p = 0.008).Table 1. Patient characteristics and cosmetic outcomes
Purpose/Objective: Male breast cancer (BC) is a rare malignancy,
accounting for approximately 1% of all male cancers and 1% of all BC cases worldwide. Due to its rarity, treatment guidelines are typically extrapolated from female BC patients. We analyzed the clinicopathologic characteristics and breast cancer outcomes of male versus female patients. Material/Methods: Using a prospectively maintained institutional database, we identified 567 men with BC treated at our institution between 2008 and 2022. These were propensity-matched to women in 2:1 fashion, yielding a cohort of 1701 patients (1134 women, 567 men). Analyses of demographics, tumor characteristics, treatment modalities, and oncologic outcomes were undertaken. Results: Among men, the median age at diagnosis was 65.3 years, 88% had a mastectomy, and 56% underwent SLNB. Most tumors were ER+ (98%) and PR+ (86%); 9.0% were HER2+, 41% had lymphovascular invasion, and 31% were high grade. In propensity-matched analyses, there was no difference in 10-year local recurrence: 4.9% among men vs 6.2% among women; p= 0.5. Distant recurrence at 10 years also did not differ between men and women (13% each; p=0.6). Similarly, 10-year disease-free and overall survival rates did not differ significantly between men and women (61% vs. 64%; p = 0.3, and 69% vs. 73%; p = 0.3, In this propensity-matched-cohort analysis of male versus female breast cancer, there was no discernible difference in oncologic outcomes between the sexes. Local and distant recurrence rates, as well as disease- free and overall survival rates, were not statistically different between men and women, suggesting that current therapeutic approaches may be equally respectively). Conclusion: effective regardless of patient sex. Efforts to evaluate male-directed treatment approaches may further improve these outcomes. Keywords: Male, Breast, Radiation
Conclusion: Our prospective cohort study showed that capsular grading and rippling were not correlated to radiation dose and field design. However, RT volume may adversely affect BAD and cleavage formation, potentially due to radiation-induced soft tissue fibrosis and skin thickening, reducing breast flexibility. Keywords: Post-Mastectomy, Breast reconstruction, Cosmesis
Made with FlippingBook - Share PDF online